We are live on ! Find out more
YMAB

Y-mAbs Therapeutics
YMAB

Delisted

YMAB was delisted on the 15th of September, 2025.

Back to rankings

81 hedge funds and large institutions have $606M invested in Y-mAbs Therapeutics in 2019 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 38 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

322% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 9

300% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 7

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

77% more capital invested

Capital invested by funds: $342M → $606M (+$264M)

25% more funds holding

Funds holding: 65 → 81 (+16)

10.41% more ownership

Funds ownership: 38.43% → 48.84% (+10%)

Holders
81
Holders Change
+16
Holders Change %
+24.62%
% of All Funds
1.6%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.06%
New
28
Increased
38
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$60.5M
2
CAM
Cormorant Asset Management
Massachusetts
+$21.3M
3
BlackRock
BlackRock
New York
+$20.4M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$16.1M
5
State Street
State Street
Massachusetts
+$11.7M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$21.8M
2
PA
Perceptive Advisors
New York
-$8.66M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.97M
4
Stifel Financial
Stifel Financial
Missouri
-$2.61M
5
AA
ALPS Advisors
Colorado
-$1.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
26
Baker Bros. Advisors
New York
$4.33M +$1.06M +35,714 +35%
Charles Schwab
27
Charles Schwab
California
$3.7M +$928K +31,374 +36%
N
28
Nuveen
North Carolina
$3.3M +$629K +21,254 +25%
Bank of America
29
Bank of America
North Carolina
$2.7M +$815K +27,538 +47%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.62M +$735K +24,831 +42%
Squarepoint
31
Squarepoint
New York
$2.27M +$686K +23,174 +47%
Citadel Advisors
32
Citadel Advisors
Florida
$2.2M +$2.08M +70,328 New
SSA
33
Schonfeld Strategic Advisors
New York
$2.02M +$1.91M +64,600 New
CS
34
Candriam SCA
Luxembourg
$1.8M +$1.7M +57,526 New
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$1.54M +$1.46M +49,428 New
VIA
36
Vident Investment Advisory
Georgia
$1.49M -$496K -16,761 -26%
Two Sigma Advisers
37
Two Sigma Advisers
New York
$1.35M +$1.28M +43,300 New
RHJA
38
Rice Hall James & Associates
California
$1.24M +$1.17M +39,566 New
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$1.23M +$878K +29,670 +304%
Swiss National Bank
40
Swiss National Bank
Switzerland
$1.17M +$731K +24,700 +194%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$1.13M +$130K +4,403 +14%
JP Morgan Chase
42
JP Morgan Chase
New York
$1.07M -$28.5K -963 -3%
AR
43
Advisory Research
Illinois
$1.06M +$1M +33,951 New
CS
44
Credit Suisse
Switzerland
$976K +$646K +21,830 +232%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$956K – – –
Barclays
46
Barclays
United Kingdom
$878K +$454K +15,361 +121%
Voloridge Investment Management
47
Voloridge Investment Management
Florida
$855K +$809K +27,344 New
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$851K +$153K +5,169 +23%
Renaissance Technologies
49
Renaissance Technologies
New York
$813K -$1.32M -44,700 -63%
SO
50
STRS Ohio
Ohio
$737K +$44.4K +1,500 +7%
1
2
3 4

YMAB Hedge Fund Activity: Q4 2019 in Review

81 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q4 2019, worth a combined $606M — up 77% from $342M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new YMAB positions and 7 closed out — a net gain of 21 holders — while 38 added to existing stakes and 9 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $60.5M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $21.8M sold.

  • 81 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q4 2019, up from 65 in Q3 2019.
  • Funds reported $606M of Y-mAbs Therapeutics stock for Q4 2019, up 77% quarter-over-quarter.
  • 28 funds opened new Y-mAbs Therapeutics positions in Q4 2019 and 7 closed out, a net change of +21 holders.
  • The largest Y-mAbs Therapeutics buyer in Q4 2019 was Wellington Management Group, an estimated $60.5M added.
  • The largest Y-mAbs Therapeutics seller in Q4 2019 was T. Rowe Price Associates, an estimated $21.8M sold.

Based on aggregated 13F filings for Q4 2019.